Assessment of platelet inhibitory response to clopidogrel when coadministered with a proton pump inhibitor - Plavix and PPI study
Phase 1
- Conditions
- To investigate in patients undergoing elective coronary stenting, the interaction between omeprazole, rabeprazole and ranitidine on clopodogrel inhibition of platelet activity in wild type (wt/wt) CYP2C19 extensive metabolisers”, using VerifyNow-P2Y12 assay clopidogrel assay. We will also indirectly assess the effect of clopidogrel on acid suppression by measuring gastrin hormone levels that are directly related to stomach pH.
- Registration Number
- EUCTR2009-011543-40-GB
- Lead Sponsor
- Papworth Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Age >18
Able to consent
Elective PCI
Bleeding risk (eScore>15) and indication for PPI when on DAP
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Allergic to omeprazole, rabeprazole or ranitidine
Already on a PPI
Pregnant
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method